Tim Cundy

Summary

Affiliation: University of Auckland
Country: New Zealand

Publications

  1. ncbi Reprint: Paget's disease of bone
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
    Clin Biochem 45:970-5. 2012
  2. ncbi Recent advances in osteogenesis imperfecta
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Calcif Tissue Int 90:439-49. 2012
  3. ncbi Proposed new diagnostic criteria for gestational diabetes--a pause for thought?
    T Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Diabet Med 29:176-80. 2012
  4. ncbi Paget's disease of bone
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
    Clin Biochem 45:43-8. 2012
  5. ncbi Evidence for secular change in Paget's disease
    T Cundy
    Department of Medicine, University of Auckland Medical School, New Zealand
    Bone 20:69-71. 1997
  6. ncbi Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 19:703-11. 2004
  7. ncbi Familial Paget disease and SQSTM1 mutations in New Zealand
    Tim Cundy
    Department of Medicine, University of Auckland, New Zealand
    Calcif Tissue Int 89:258-64. 2011
  8. ncbi Severe hypomagnesaemia in long-term users of proton-pump inhibitors
    T Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Clin Endocrinol (Oxf) 69:338-41. 2008
  9. ncbi Differing causes of pregnancy loss in type 1 and type 2 diabetes
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Diabetes Care 30:2603-7. 2007
  10. ncbi Is the prevalence of Paget's disease of bone decreasing?
    Tim Cundy
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 21:P9-13. 2006

Detail Information

Publications64

  1. ncbi Reprint: Paget's disease of bone
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
    Clin Biochem 45:970-5. 2012
    ..To review recent advance in understanding the causation and management of Paget's disease...
  2. ncbi Recent advances in osteogenesis imperfecta
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Calcif Tissue Int 90:439-49. 2012
    ....
  3. ncbi Proposed new diagnostic criteria for gestational diabetes--a pause for thought?
    T Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Diabet Med 29:176-80. 2012
    ..Given the many reservations about the new criteria an urgent but dispassionate debate is required on the risks, costs and benefits of their introduction...
  4. ncbi Paget's disease of bone
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
    Clin Biochem 45:43-8. 2012
    ..To review recent advance in understanding the causation and management of Paget's disease...
  5. ncbi Evidence for secular change in Paget's disease
    T Cundy
    Department of Medicine, University of Auckland Medical School, New Zealand
    Bone 20:69-71. 1997
    ..Our data demonstrate that, on average, newly referred patients with Paget's disease have less severe disease and are significantly older at diagnosis than was the case two decades ago...
  6. ncbi Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 19:703-11. 2004
    ..Their youngest affected sibling was treated intensively with intravenous bisphosphonates for 3 years. The treatment was well tolerated and prevented the development of deformity and disability...
  7. ncbi Familial Paget disease and SQSTM1 mutations in New Zealand
    Tim Cundy
    Department of Medicine, University of Auckland, New Zealand
    Calcif Tissue Int 89:258-64. 2011
    ..005). SQSTM1 mutations were found in 10.5% of patients with early onset and/or severe disease but no family history...
  8. ncbi Severe hypomagnesaemia in long-term users of proton-pump inhibitors
    T Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Clin Endocrinol (Oxf) 69:338-41. 2008
    ..To explore the mechanism underlying severe hypomagnesaemia in long-term users of proton-pump inhibitors (PPIs)...
  9. ncbi Differing causes of pregnancy loss in type 1 and type 2 diabetes
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Diabetes Care 30:2603-7. 2007
    ..Women with type 2 and type 1 diabetes have differing risk factors for pregnancy loss. We compared the rates and causes of pregnancy loss in women with type 1 and type 2 diabetes...
  10. ncbi Is the prevalence of Paget's disease of bone decreasing?
    Tim Cundy
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 21:P9-13. 2006
    ..Paget's disease has become less prevalent and patients are presenting later, with less severe disease than previously. These data suggest that environmental factors are important in the etiology of Paget's disease...
  11. ncbi Is Paget's disease of bone disappearing?
    T Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, 1001, New Zealand
    Skeletal Radiol 35:350-1. 2006
  12. ncbi Paget disease of bone
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Trends Endocrinol Metab 19:246-53. 2008
    ..Most observations seem to fit best with the idea that Paget disease behaves as a multifocal benign neoplasm...
  13. ncbi Proton pump inhibitors and severe hypomagnesaemia
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Curr Opin Gastroenterol 27:180-5. 2011
    ..We reviewed all the cases published to date in peer-reviewed journals to summarize what is known of the epidemiology, risk factors, cause and treatment...
  14. ncbi Bone formation markers in adults with mild osteogenesis imperfecta
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Clin Chem 53:1109-14. 2007
    ..Plasma concentrations of procollagen peptides are decreased in osteogenesis imperfecta (OI), whereas other bone formation markers may be increased. We examined the utility of combining these markers in the diagnosis of OI in adults...
  15. ncbi Idiopathic hyperphosphatasia
    Tim Cundy
    Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand
    Semin Musculoskelet Radiol 6:307-12. 2002
    ..Treatment with inhibitors of bone resorption (calcitonin or bisphosphonates) is successful in ameliorating some aspects of the disorder...
  16. ncbi A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate
    Tim Cundy
    Department of Medicine, Faculty of Medicine and Health Science, University of Auckland, 1001 Auckland, New Zealand
    J Clin Endocrinol Metab 88:78-81. 2003
    ..0%, P = 0.029). There were no major adverse events. These data support the view that the likely cause of DMPA-associated bone loss is estrogen deficiency and demonstrate that it can be arrested by estrogen replacement therapy...
  17. ncbi A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype
    Tim Cundy
    Department of Medicine, Faculty of Medicine and Health Science, University of Auckland, New Zealand
    Hum Mol Genet 11:2119-27. 2002
    ..This description of abnormal OPG function in humans expands the spectrum of genetic bone diseases arising from perturbations of the OPG/RANK-L/RANK system that regulates osteoclastogenesis...
  18. ncbi Hypertensive disorders of pregnancy in women with Type 1 and Type 2 diabetes
    T Cundy
    Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland and, Diabetes Pregnancy Clinic, National Women s Hospital, Auckland, New Zealand
    Diabet Med 19:482-9. 2002
    ..The aim of this study was to compare the incidence and outcomes of, and risk factors for, hypertension in pregnancy in women with Type 1 and Type 2 diabetes...
  19. ncbi Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception
    Tim Cundy
    Department of Medicine, Faculty of Medicine and Health Science, The University of Auckland, and the Family Planning Association of New Zealand
    Am J Obstet Gynecol 186:978-83. 2002
    ..The purpose of this study was to determine the rate of early postmenopausal bone loss in women who had used depot medroxyprogesterone acetate contraception through to menopause...
  20. ncbi Spinal bone density in women using depot medroxyprogesterone contraception
    T Cundy
    Department of Medicine, The Faculty of Medicine and Health Sciences, University of Auckland, New Zealand
    Obstet Gynecol 92:569-73. 1998
    ..To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot medroxyprogesterone acetate...
  21. ncbi Perinatal mortality in Type 2 diabetes mellitus
    T Cundy
    Department of Medicine, University of Auckland, New Zealand
    Diabet Med 17:33-9. 2000
    ..This study reports observational data on perinatal mortality in Type 2 DM from a population with a high background rate of this disorder...
  22. ncbi Absence of somatic SQSTM1 mutations in Paget's disease of bone
    Brya G Matthews
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
    J Clin Endocrinol Metab 94:691-4. 2009
    ..Therefore, we examined the possibility that somatic mutations in the SQSTM1 gene are present in the local lesions, using RNA collected from primary osteoblast and bone marrow cell cultures of patients with this condition...
  23. ncbi Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Clin Endocrinol Metab 92:2446-52. 2007
    ..EXPERIMENTAL SUBJECTS: Subjects included 80 women with postmenopausal osteoporosis who had been taking estrogen for at least 1 yr...
  24. ncbi Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease
    Brya G Matthews
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
    J Clin Endocrinol Metab 93:1398-401. 2008
    ..We have tested for measles virus sequences in osteoblasts and bone marrow cells collected from pagetic lesions and healthy bone...
  25. ncbi Recombinant osteoprotegerin for juvenile Paget's disease
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    N Engl J Med 353:918-23. 2005
    ..Apart from mild hypocalcemia and hypophosphatemia, no apparent adverse events occurred...
  26. ncbi Increased abdominal fat in young women of Indian origin
    Brandon Orr-Walker
    Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand
    Asia Pac J Clin Nutr 14:69-73. 2005
    ..001), with marked differences evident even in the youngest group (mean age 23 years). Compared to other racial groups, women of Indian origin preferentially accumulate abdominal fat--a trait that is well established in young adulthood...
  27. ncbi Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations
    Mark J Bolland
    Department of Medicine, University of Auckland, New Zealand
    J Bone Miner Res 22:411-5. 2007
    ..At any given age, the offspring were less likely to be diagnosed with Paget's disease and had less severe disease than their parents...
  28. ncbi Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand?
    Mark J Bolland
    Bone and Joint Research Group, Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
    N Z Med J 125:83-91. 2012
    ..Therefore, a move away from routine vitamin D measurements seems sensible, though they are still indicated when investigating suspected metabolic bone disease or hypocalcaemia...
  29. ncbi Insulin sensitivity in the offspring of women with type 1 and type 2 diabetes
    Wendy A Hunter
    Liggins Institute, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland, New Zealand
    Diabetes Care 27:1148-52. 2004
    ..To determine if insulin sensitivity is altered in prepubertal offspring exposed to a diabetic intrauterine environment...
  30. ncbi Osteonecrosis of the jaw
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Skeletal Radiol 38:5-9. 2009
    ..Obvious abnormalities are apparent with a variety of radiologic modalities, and it is not clear that radiographs are inferior to other approaches. Most authors favor a conservative approach to surgical debridement of the lesions...
  31. ncbi Osteonecrosis of the jaw and bisphosphonates--putting the risk in perspective
    Mark Bolland
    Department of Medicine, University of Auckland
    N Z Med J 119:U2339. 2006
    ..The aim of this article is to put the risks of osteonecrosis of the jaw into context with the benefits of bisphosphonate treatment in these clinical scenarios...
  32. ncbi Paget's disease of bone in New Zealand: continued decline in disease severity
    H R Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
    Calcif Tissue Int 75:358-64. 2004
    ..Although there are a number of potential biases, these data are consistent with a continued secular trend to presentation in older subjects with less extensive skeletal involvement, and a declining prevalence of Paget's disease...
  33. ncbi Understanding the new HbA1c units for the diagnosis of Type 2 diabetes
    Geoff D Braatvedt
    Department of Medicine, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    N Z Med J 125:70-80. 2012
    ..For patients whose HbA1c is less than and equal to 40 mmol/mol, repeat screening (including for CVD risk) at intermittent intervals is recommended as per published guidelines...
  34. ncbi Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone
    Ian R Reid
    Department of Medicine, University of Auckland, Private Bag 92019, New Zealand
    Bone 35:224-30. 2004
    ..There is no clear evidence from this study that any of these newer markers are superior to total AP in assessing patients with this severity of Paget's disease...
  35. ncbi Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone
    Dorit Naot
    Department of Medicine, University of Auckland, New Zealand
    J Bone Miner Res 22:298-309. 2007
    ..We identified several differentially regulated genes, and we suggest that these changes could lead to the formation of the lesions...
  36. ncbi Paget's disease of bone--becoming a rarity?
    Sonja Bastin
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1020, New Zealand
    Rheumatology (Oxford) 48:1232-5. 2009
    ..We undertook a radiographic survey to determine the current prevalence of Paget's disease in New Zealand (previously recognized as a high prevalence area)...
  37. ncbi Peak bone mass after exposure to antenatal betamethasone and prematurity: follow-up of a randomized controlled trial
    Stuart R Dalziel
    Clinical Trials Research Unit, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 21:1175-86. 2006
    ..Birth weight and prematurity predict adult height, but it is slower fetal growth, rather than prematurity, that predicts lower peak bone mass. The lower peak bone mass in those born small is appropriate for their adult height...
  38. ncbi Increasing prevalence of type 2 diabetes in adolescents
    S Hotu
    Auckland Diabetes Centre, Auckland, New Zealand
    J Paediatr Child Health 40:201-4. 2004
    ..Adverse cardiovascular risk factors are prevalent in this population. Public health measures to curtail the rise of obesity in childhood and adolescence are required urgently...
  39. ncbi Long-term maternal outcome after pregnancy in women with diabetic nephropathy
    Warwick Bagg
    Pregnancy Diabetes Clinic, National Women's Hospital and Department of Medicine, University of Auckland, Auckland, New Zealand
    N Z Med J 116:U566. 2003
  40. ncbi Metformin versus insulin for the treatment of gestational diabetes
    Janet A Rowan
    National Women s Health, Auckland City Hospital, Grafton, Auckland, New Zealand
    N Engl J Med 358:2003-15. 2008
    ..Metformin is a logical treatment for women with gestational diabetes mellitus, but randomized trials to assess the efficacy and safety of its use for this condition are lacking...
  41. ncbi Congenital anomalies in the offspring of women with type 1, type 2 and gestational diabetes
    T Farrell
    Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, New Zealand
    Diabet Med 19:322-6. 2002
    ..In the remainder of the GDM group, the rate does not differ from the non-diabetic background rate...
  42. ncbi Paget's disease in patients of Asian descent in New Zealand
    Shyam Sankaran
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Aukland, New Zealand
    J Bone Miner Res 27:223-6. 2012
    ..It also implies that the apparent reduction in Paget's disease prevalence in western cities is unlikely to be explicable by the rising Asian population of these cities...
  43. ncbi The effect of an apparent change to a branded or generic medication on drug effectiveness and side effects
    Kate Faasse
    Department of Psychological Medicine, University of Auckland, Auckland 1142, New Zealand
    Psychosom Med 75:90-6. 2013
    ..This study examined the effect of an apparent medication formulation change on subjective and objective measures of medication effectiveness and medication side effects...
  44. ncbi Ocular manifestations of juvenile Paget disease
    Nathan M Kerr
    Department of Ophthalmology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Arch Ophthalmol 128:698-703. 2010
    ..To determine the prevalence and spectrum of retinal changes in juvenile Paget disease...
  45. ncbi Lifetime risk of symptomatic carpal tunnel syndrome in Type 1 diabetes
    R Singh
    Auckland Diabetes Centre, Auckland, New Zealand
    Diabet Med 22:625-30. 2005
    ..To determine the lifetime risk of developing symptomatic carpal tunnel syndrome (CTS) in subjects with Type 1 diabetes and to investigate the effect of glycaemic control, body mass index (BMI), gender and age of onset of diabetes...
  46. ncbi Bisphosphonate space measurement and dosage requirement for intravenous clodronate treatment of Paget's disease
    M Rutland
    Department of Nuclear Medicine, Auckland Hospital, Auckland, New Zealand
    Calcif Tissue Int 70:99-102. 2002
    ..Both ALP and the bisphosphonate space have wide prediction intervals, and are therefore poor guides to dose requirement...
  47. ncbi Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment
    S Rudge
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1, New Zealand
    Rheumatology (Oxford) 44:813-8. 2005
    ..This study highlights the importance of differentiating between changes in bone size and changes in volumetric bone density in assessing bone in children, and also having control subjects in intervention studies...
  48. ncbi Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease
    Noriyoshi Kurihara
    Department of Medicine/Hematology and Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Bone Miner Res 19:1154-64. 2004
    ..TAFII-17 can bind VDR at low concentrations of 1,25(OH)2D3. These results suggest that MVNP expression in Paget's OCL precursors increases expression of a component(s) of the VDR transcription complex that can increase OCL formation...
  49. ncbi (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease
    Seiichi Ishizuka
    Veterans Affairs Pittsburgh Healthcare System, Research and Development (151-U, University Drive, Pittsburgh, Pennsylvania 15240, USA
    Endocrinology 146:2023-30. 2005
    ..These results demonstrate that TEI-9647 can suppress the excessive bone resorption and OCL formation seen in marrow cultures from patients with PD...
  50. ncbi Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells
    Seiichi Ishizuka
    Department of Bone and Calcium Metabolism, Teijin Institute for Bio Medical Research, Hino, Tokyo, Japan
    J Steroid Biochem Mol Biol 89:331-4. 2004
    ..These results suggest that TEI-9647 acts directly on osteoclast precursors and osteoclasts, and that TEI-9647 may be a novel agent to suppress the excessive bone resorption and osteoclast formation in patients with Paget's disease...
  51. ncbi Bisphosphonates and osteonecrosis of the jaw
    Andrew Grey
    Ann Intern Med 145:791; author reply 792. 2006
  52. ncbi Why do poor outcomes persist in diabetic pregnancy?
    Tim Cundy
    BMJ 333:304. 2006
  53. ncbi Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin
    Anna Daroszewska
    Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen AB25 2ZD, UK
    J Bone Miner Res 19:1506-11. 2004
    ..We found that the G1181 allele of TNFRSF11B, encoding lysine at codon 3 of the OPG protein, predisposes to both sporadic and familial PDB...
  54. ncbi Evaluation of the role of Valosin-containing protein in the pathogenesis of familial and sporadic Paget's disease of bone
    Gavin J A Lucas
    Department of Medicine and Therapeutics, University of Aberdeen, UK
    Bone 38:280-5. 2006
    ..Genetic variation in VCP does not appear to be a common cause of familial or sporadic PDB in the absence of myopathy and dementia...
  55. ncbi Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine
    Barbara A Cromer
    Case School of Medicine, Cleveland, Ohio, USA
    J Adolesc Health 39:296-301. 2006
    ....
  56. ncbi Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease
    William E Friedrichs
    Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, USA
    J Bone Miner Res 17:145-51. 2002
    ..These findings are consistent with the presence of a chronic MV infection in affected sites from these patients with Paget's disease...
  57. ncbi Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease
    Lynne J Hocking
    Department of Medicine and Therapeutics, University of Aberdeen, UK
    Hum Mol Genet 11:2735-9. 2002
    ..0001). These studies confirm that mutations affecting the ubiquitin-binding domain of SQSTM1 are a common cause of familial and sporadic Paget's disease of bone...
  58. ncbi The deleted in colorectal carcinoma (DCC) gene 201 R --> G polymorphism: no evidence for genetic association with autoimmune disease
    Richard J Hall
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Eur J Hum Genet 11:840-4. 2003
    ..Thus, the DCC 201 R --> G polymorphism does not appreciably influence risk of developing the autoimmune diseases tested...
  59. ncbi Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis, and structural consequences
    Lynne J Hocking
    Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom
    J Bone Miner Res 19:1122-7. 2004
    ..Functional and structural analysis showed that disease severity was related to the type of mutation but was unrelated to the polyubiquitin-binding properties of the mutant UBA domain peptides...
  60. ncbi Defining vitamin D deficiency
    Mark J Bolland
    N Z Med J 120:U2760. 2007
  61. ncbi Identification of a major locus for Paget's disease on chromosome 10p13 in families of British descent
    Gavin Ja Lucas
    Rheumatic Diseases Unit, University of Edinburgh, Edinburgh, United Kingdom
    J Bone Miner Res 23:58-63. 2008
    ..A major susceptibility locus for PDB was identified on chromosome 10p13 by a genome-wide linkage scan in families of British descent, which accounted for the vast majority of cases not caused by SQSTM1 mutations...
  62. ncbi Recovery from skeletal fluorosis
    Tim Cundy
    J Bone Miner Res 22:1475; author reply 1476. 2007
  63. ncbi Itraconazole-induced painful neuropathy in a man with type 1 diabetes
    Rinki Singh
    Diabetes Care 28:225. 2005
  64. ncbi Ubiquitin-associated domain mutations of SQSTM1 in Paget's disease of bone: evidence for a founder effect in patients of British descent
    Gavin J A Lucas
    Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom
    J Bone Miner Res 20:227-31. 2005
    ..Here we show that the most common disease-causing mutation (P392L) is carried on a shared haplotype, consistent with a founder effect and a common ancestral origin...